How Europe’s Mixed Messages On AstraZeneca Could Jeopardize The Global Covid Response | Forbes

Published 3 years ago
hqdefault

In March, more than a dozen European countries suspended use of AstraZeneca’s COVID-19 vaccine because of concerns over blood clotting.

AstraZenica has said the clotting is not related to the vaccine. And while the WHO and European Medicines Agency are both conducting additional reviews of the vaccine, they said countries should not have suspended use of the vaccine. Experts are worried these steps could erode people’s willingness to get the vaccine.

Advertisement

Largely due to an inadequate supply of doses, The European Union has lagged behind other countries in terms of the vaccine rollout, with fewer than 11.4 vaccinations for every 100 people as of March. By comparison, the U.S. has 32.6 vaccinations per hundred people, and the U.K. leads the pack with 38.4 per hundred.

This kind of fear could have global implications if enough people choose not to get vaccinated.

Read the full profile on Forbes: https://www.forbes.com/sites/katiejennings/2021/03/16/europes-mixed-messages-on-astrazeneca-vaccine-jeopardize-global-covid-response/?sh=1d10c7bc1119

Subscribe to FORBES: https://www.youtube.com/user/Forbes?sub_confirmation=1

Advertisement

Stay Connected
Forbes newsletters: https://newsletters.editorial.forbes.com
Forbes on Facebook: http://fb.com/forbes
Forbes Video on Twitter: http://www.twitter.com/forbes
Forbes Video on Instagram: http://instagram.com/forbes
More From Forbes: http://forbes.com

Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.